Back to Market Feed

Product Information

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by Endo USA Inc., priced at $2.3760 per EA under NDC 49884015154. Its NADAC has been published 136 times since Jan 17, 2024.

FDA first approved this application on Mar 6, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE

Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride
$2.3760per EA

Strength

140; 125; 125 mg/1; mg/1; mg/1

Manufacturer

Endo USA Inc.

NDC

49884015154

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA205770

FDA Approved

3/6/2023

TE Code

AB

On Market Since

3/7/2023

Pharmacological Classes

Bismuth
Bismuth
Nitroimidazole Antimicrobial
Nitroimidazoles
Tetracycline-class Antimicrobial
Tetracyclines

Price Statistics

The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 136 times since Jan 17, 2024, and over the history we have for it it has declined 53.7%. The table below summarizes its recorded NADAC range and movement.

Current price$2.3760 per EA
All-time high$5.1282 (Feb 14, 2024)
All-time low$2.3760 (Aug 19, 2026)
52-week high$4.0294
52-week low$2.3760
Median price$3.6473
Average price$3.5819
Largest weekly change-22.6% (Jul 17, 2024)
Weeks tracked136
Tracking sinceJan 17, 2024

Price History

1W

-0.1%

1M

-0.1%

3M

-10.6%

6M

-25.3%

1Y

-41.0%

3Y

N/A

5Y

N/A

All

-53.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

STOMACH RELIEF 525 MG/15 ML
Generic
70000004501•Cardinal Health
$0.0096
per ML
HM STOMACH RELIEF 525 MG/15 ML
Generic
62011043601•Strategic Sourcing Services LLC
$0.0100
per ML
HM STOMACH RELIEF 525 MG/30 ML
Generic
62011043501•Strategic Sourcing Services LLC
$0.0106
per ML
SM STOMACH RELIEF 525 MG/30 ML
Generic
70677009401•Strategic Sourcing Services LLC
$0.0106
per ML
STOMACH RELIEF 525 MG/15 ML
Generic
00536128736•Rugby Laboratories
$0.0110
per ML
GNP PINK BISMUTH 525 MG/15 ML
Generic
46122074706•AmerisourceBergen
$0.0121
per ML
STOMACH RLF 525 MG/30 ML SUSP
Generic
00536128636•Rugby Laboratories
$0.0122
per ML
STOMACH RELIEF 525 MG/30 ML
Generic
70000069801•Cardinal Health
$0.0126
per ML
FT STOMACH RELIEF 525 MG/30 ML
Generic
70677119101•Strategic Sourcing Services LLC
$0.0126
per ML
GNP STOMACH RLF 525 MG/30 ML
Generic
46122070326•AmerisourceBergen
$0.0168
per ML

Frequently asked questions

What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by Endo USA Inc., is $2.3760 per EA (NDC 49884015154), effective Aug 19, 2026.

How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 53.7%. It has been tracked across 136 weekly CMS publications since Jan 17, 2024.

What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

Since Jan 17, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $5.1282 (Feb 14, 2024), with a median of $3.6473 per EA.

Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 49884015154) is labeled by Endo USA Inc., and CMS classifies it as a generic product.